Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.34 USD
-0.03 (-7.76%)
Updated Jun 5, 2024 03:59 PM ET
After-Market: $0.35 +0.01 (2.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 181 - 192 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Exclusive Non-Invasive Companion Diagnostic for Aramchol; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Clearing Up Fat and Inflammation Safely in NASH; Initiate with Buy and $21 Price Target
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and 12-month price target of $20/share.
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E